Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00564226 · ClinicalTrials.gov registry record · Phase 2
SSR240600C Treatment in Women With Overactive Bladder
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
NCT00564226 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 345 participants.
The verdict
NCT00564226, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.
Interventions
- DRUG placebo
- DRUG SSR240600C
- DRUG tolterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00564226
The ClinicalTrials.gov registry entry for NCT00564226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00564226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00564226 about?
NCT00564226 is a clinical study titled "SSR240600C Treatment in Women With Overactive Bladder". The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.
What is the current status of trial NCT00564226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2007-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00564226?
The interventions under investigation include: placebo (DRUG), SSR240600C (DRUG), tolterodine (DRUG).
Who is sponsoring clinical trial NCT00564226?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.